VBL Therapeutics GAAP EPS of -$0.12 in-line, revenue of $0.5M beats by $0.3M

Nov. 15, 2022 4:02 AM ETVascular Biogenics Ltd. (VBLT)By: Meghavi Singh, SA News Editor
  • VBL Therapeutics press release (NASDAQ:VBLT): Q3 GAAP EPS of -$0.12 in-line.
  • Revenue of $0.5M (+150.0% Y/Y) beats by $0.3M.
  • At September 30, 2022, VBL had cash, cash equivalents, short-term bank deposits and restricted bank deposits of $27.7M.
  • VBL expects that its cash, cash equivalents, short-term bank deposits, and restricted bank deposits will be sufficient to fund currently planned operating expenses and capital expenditures for at least twelve months. 

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.